Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJul092020	Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819 for Patients with Advanced B-cell Leukemias and Lymphomas SAN DIEGO , July 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Read All »	View HTML
Toggle SummaryJul142020	Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Durable Tumor Read All »	View HTML
Toggle SummaryJul292020	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results SAN DIEGO , July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryAug042020	Fate Therapeutics to Present at the Wedbush PacGrow Healthcare Virtual Conference SAN DIEGO , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Ph.D., Chief Scientific Officer, Read All »	View HTML
Toggle SummaryAug052020	Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy , for AML and Multiple Myeloma IND Cleared Read All »	View HTML
Toggle SummaryAug192020	Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer SAN DIEGO , Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointed Chief Financial Read All »	View HTML
Toggle SummarySep042020	Fate Therapeutics Announces September Investor Events SAN DIEGO , Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor Read All »	View HTML
Toggle SummarySep302020	Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit SAN DIEGO , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate in a fireside chat Read All »	View HTML
Toggle SummaryOct152020	Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting SAN DIEGO , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that five abstracts for the Company’s induced Read All »	View HTML
Toggle SummaryNov022020	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2020 Financial Results SAN DIEGO , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the Company will host a conference call and live Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.